<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210222050457N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-05-08</date_registration>
      <primary_sponsor>Yazd University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of herbal combination of fenugreek seeds and carrot seeds on sexual function 0fwomen with diabetes type 2,a randomized double-blinded clinical trial</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of herbal combination of fenugreek seeds and carrot seeds on sexual function of women with diabetes type 2,a randomized double-blinded clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-05-31</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69481</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: People are randomly divided to drug and placebo groups. The drug group received 500 mg herbal tablets three times a day, and the placebo group received placebo tablets with the same prescription, Blinding description: The intervention group received 500 mg herbal tablets three times a day, and the placebo group received placebo tablets with the same order.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Type 2 diabetes with sexual dysfunctionٍ.</hc_freetext>
      <i_freetext>Intervention 1: The intervention group consumes 500 mg herbal tablets three times a day. The drug is prescribed to patients for 8 weeks by a non-researcher, based on masking. The raw materials of this product, which include carrot seeds and fenugreek seeds, are first subjected to quality control tests, including the amount of waste particles, moisture, total ash, and determining the amount of an indicator substance or total essential oil. After determining the quality of each plant, 250 mg of 5% fenugreek seed extract (Fenugreek seed extract) is mixed with 250 mg of carrot seed powder and then sieved and produced in the form of 500 mg tablets with a press machine. Intervention 2: The control group consumes 500 mg placebo tablets made of starch but with a completely similar appearance to the drug three times a day. The placebo is prescribed to patients for 8 weeks by a non-researcher.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data will publish in the form of a thesis

When:
6 months after the results are published

To whom:
For researchers working in academic and scientific institutions

Conditions:
With an official letter from the Research and Technology Vice-Chancellor of Yazd University of Medical Sciences

Where to obtain:
Fatemeh Shirvanizadeh, Faculty of Persian Medicine, Ardakan, Yazd

How to obtain:
Refer to the research and technology unit of Yazd University of Medical Sciences and ask for it

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh shirvanizadeh Arani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>1st Hekmat Alley.Motahari blvd</address>
        <city>Aran and bidgol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8741646949</zip>
        <telephone>+98 31 5472 5800</telephone>
        <email>dr.shirvanizade@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fateme shirvani zade Arani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hekmat1 Alley, Motahari Blvd</address>
        <city>Aran and bidgol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8741756791</zip>
        <telephone>+98 31 5472 5800</telephone>
        <email>dr.shirvanizade@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Married women with type 2 diabetes and sexual dysfunction
HBA1C between 7.1 &amp; 8.53.
Age between 25 &amp; 55 years
diabetic patients should not have systemic diseases such as liver failure, kidney failure, heart failure, thyroid failure, central nervous system disorders, or retinopathy.
Absence of pregnancy and breastfeeding
Absence of Ovariectomy history and  Ovarian agenesis
Having a stable life with his wife
Married for at least one year</inclusion_criteria>
      <agemin>25 years</agemin>
      <agemax>55 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Diagnosis of having chronic diseases affecting sexual function in the patient or his partner during the study (such as cardiovascular or mental or thyroid disorders, cancers)
taking drugs that affect sexual performance
The occurrence of an unfortunate incident such as the loss of partner or close relative during the study
vaginal bleeding, dyspareunia, vaginismus
Getting pregnant
Menopause</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E11.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Type 2 diabetes mellitus with unspecified complications</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The intervention group consumes 500 mg herbal tablets three times a day. The drug is prescribed to patients for 8 weeks by a non-researcher, based on masking. The raw materials of this product, which include carrot seeds and fenugreek seeds, are first subjected to quality control tests, including the amount of waste particles, moisture, total ash, and determining the amount of an indicator substance or total essential oil. After determining the quality of each plant, 250 mg of 5% fenugreek seed extract (Fenugreek seed extract) is mixed with 250 mg of carrot seed powder and then sieved and produced in the form of 500 mg tablets with a press machine.</i_keyword>
      <i_keyword>The control group consumes 500 mg placebo tablets made of starch but with a completely similar appearance to the drug three times a day. The placebo is prescribed to patients for 8 weeks by a non-researcher.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sexual function. Timepoint: At the beginning of the study and after two months of taking the drug. Method of measurement: Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>FBS. Timepoint: At the beginning of the study and 60 days after starting to take the drug. Method of measurement: Lab test.</sec_outcome>
      <sec_outcome>2 hours post prandial blood sugar. Timepoint: At the beginning of the study and 60 days after starting to take the drug. Method of measurement: Lab test.</sec_outcome>
      <sec_outcome>HB A1C. Timepoint: At the beginning of the study and 60 days after starting to take the drug. Method of measurement: Lab test.</sec_outcome>
      <sec_outcome>Mental health. Timepoint: At the beginning of the study and 60 days after starting to take the drug. Method of measurement: questionare.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yazd University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-03-05</approval_date>
        <contact_name>Ethical Committee of Shahid Dr. Rahnamun Hospital, Yazd</contact_name>
        <contact_address>Motahari Blvd., end of 1st Hekmat Alley Aran and bidgol Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
